Physician profile
James E Dechavez
NPI 1598277378
$4,753.23
in general payments reported to CMS, 2019-2025
31 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $479 · 2022: $1,149 · 2023: $1,140 · 2024: $858 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,100 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,100.38 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $811.01 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $716.86 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $561.64 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $475.24 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $352.69 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $288.65 | 2021-2025 | |
| Corcept Therapeutics | $252.19 | 2022-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $125.50 | 2021-2023 | Trintellix |
| Exact Sciences Corporation | $114.39 | 2023-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $104.70 | 2021-2023 | Nexletol, Contrave, Nexlizet |
| Antares Pharma, INC. | $102.80 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Amgen INC. | $97.93 | 2021-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $94.25 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $92.30 | 2022-2024 | Spravato |
| Pfizer INC. | $88.27 | 2022-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $80.44 | 2022-2024 | Freestyle Libre, Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $75.52 | 2021-2023 | |
| Amarin Pharma, INC. | $52.99 | 2021-2022 | |
| Tris Pharma INC | $40.59 | 2023 | Dyanavel Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $37.79 | 2022 | |
| Phathom Pharmaceuticals, INC. | $37.31 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $18.64 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.96 | 2024 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $16.07 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.98 | 2022 | |
| Clarus Therapeutics INC. | $15.85 | 2021 | |
| Medtronic, INC. | $14.10 | 2023 | Intellis Adaptivestim |
| Astellas Pharma US INC | $13.50 | 2022 | |
| Althera Pharmaceuticals LLC | $13.43 | 2021 | |
| Vistapharm, INC. | $12.72 | 2021 | |
| Paratek Pharmaceuticals, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dechavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.